99 related articles for article (PubMed ID: 10887044)
1. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
[TBL] [Abstract][Full Text] [Related]
2. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
[TBL] [Abstract][Full Text] [Related]
4. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
6. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Webb A; Cunningham D; Scarffe JH; Harper P; Norman A; Joffe JK; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
J Clin Oncol; 1997 Jan; 15(1):261-7. PubMed ID: 8996151
[TBL] [Abstract][Full Text] [Related]
8. One-day DCF regimen in patients with metastatic gastric cancer.
Dirican A; Kucukzeybek Y; Tarhan MO; Somali I; Erten C; Demir L; Can A; Bayoglu IV; Akyol M; Ekinci N; Medeni M; Koyuncu B; Alacacioglu A
Tumori; 2013; 99(2):145-8. PubMed ID: 23748805
[TBL] [Abstract][Full Text] [Related]
9. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
Kelsen D; Atiq OT; Saltz L; Niedzwiecki D; Ginn D; Chapman D; Heelan R; Lightdale C; Vinciguerra V; Brennan M
J Clin Oncol; 1992 Apr; 10(4):541-8. PubMed ID: 1548519
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
11. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Murad AM; Santiago FF; Petroianu A; Rocha PR; Rodrigues MA; Rausch M
Cancer; 1993 Jul; 72(1):37-41. PubMed ID: 8508427
[TBL] [Abstract][Full Text] [Related]
12. An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.
Klein HO; Wils J; Bleiberg H; Buyse M; Duez N
Med Oncol Tumor Pharmacother; 1989; 6(2):171-4. PubMed ID: 2664372
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
Ajani JA; Goudeau P; Levin B; Faintuch JS; Abbruzzese JL; Boman BM; Kanojia MD
Cancer Chemother Pharmacol; 1989; 24(1):41-4. PubMed ID: 2720890
[TBL] [Abstract][Full Text] [Related]
14. [Sequential dose of methotrexate and 5-fluorouracil in advanced gastric cancer--response, survival time and toxicity].
Urabe T; Akazawa S; Yoshida S
Nihon Gan Chiryo Gakkai Shi; 1986 May; 21(4):805-13. PubMed ID: 3760644
[No Abstract] [Full Text] [Related]
15. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
Bojic M; Pluschnig U; Zacherl J; Thallinger CM; Ba-Ssalamah A; Maresch J; Datler P; Schoppmann SF; Hejna M
Anticancer Res; 2011 Jun; 31(6):2379-82. PubMed ID: 21737668
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
Van Hoef ME; Baumann I; Lange C; Luft T; de Wynter EA; Ranson M; Morgenstern GR; Yvers A; Dexter TM; Testa NG
Ann Oncol; 1994 Mar; 5(3):217-24. PubMed ID: 7514434
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
Songun I; Keizer HJ; Hermans J; Klementschitsch P; de Vries JE; Wils JA; van der Bijl J; van Krieken JH; van de Velde CJ
Eur J Cancer; 1999 Apr; 35(4):558-62. PubMed ID: 10492627
[TBL] [Abstract][Full Text] [Related]
19. [Sequential methotrexate and 5-fluorouracil].
Sasaki T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1907-10. PubMed ID: 8978795
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.
Aitini E; Rabbi C; Mambrini A; Cavazzini G; Pari F; Zamagni D; Cantore M; Pagani M; Sorio M; Lusenti A; Adami F; Smerieri F
Tumori; 2001; 87(1):20-4. PubMed ID: 11669552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
